Quince Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-06-11.
Quince Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on June 11, 2026. Quince Therapeutics, Inc. trades on Nasdaq as IRLA. The filing reports $114.72M sold. Its industry group is Biotechnology. It names Dirk Thye (Executive Officer, Director), Brigette Roberts (Executive Officer, Director), Charles Ryan (Executive Officer) (SEC Form D, June 11, 2026).
In its own words: “IRulya was founded to pursue an approach that impacts the underlying disease biology and delivers such therapy directly to the site of disease in the lungs.” (irulya.com, checked October 31, 2026)
Who owns Quince Therapeutics, Inc.?
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Quince Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-06-11 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Quince Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Quince Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in June 2026, largest first.
Get an email when Quince Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Quince Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Quince Therapeutics, Inc. →Get the full cited report on Quince Therapeutics, Inc.
What the filing shows about Quince Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Quince Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Quince Therapeutics, Inc.'s address as 611 Gateway Blvd., Suite 273, South San Francisco, CA 94080.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Quince Therapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Quince Therapeutics, Inc. See pricing
Quince Therapeutics, Inc. is a registered filer with the SEC (CIK 1662774) and has filed since 2025-07-01. 3 filings are on record, the latest on 2026-06-11.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Quince Therapeutics, Inc.'s Form D of 2026-06-11 names Dirk Thye, Brigette Roberts, Charles Ryan and 4 more as its officers, directors or promoters.
Its new offerings report $126.21M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $114.72M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Dirk Thye is named as Executive Officer and Director on the Form D that Quince Therapeutics, Inc. filed with the SEC on 11 June 2026, one of 7 people that filing names.
Brigette Roberts is named as Executive Officer and Director on the Form D that Quince Therapeutics, Inc. filed with the SEC on 11 June 2026, one of 7 people that filing names.
Charles Ryan is named as Executive Officer on the Form D that Quince Therapeutics, Inc. filed with the SEC on 11 June 2026, one of 7 people that filing names.
Brendan Hannah is named as Executive Officer on the Form D that Quince Therapeutics, Inc. filed with the SEC on 11 June 2026, one of 7 people that filing names.
David Lamond is named as Director on the Form D that Quince Therapeutics, Inc. filed with the SEC on 11 June 2026, one of 7 people that filing names.
Christopher Senner is named as Director on the Form D that Quince Therapeutics, Inc. filed with the SEC on 11 June 2026, one of 7 people that filing names.
June Bray is named as Director on the Form D that Quince Therapeutics, Inc. filed with the SEC on 11 June 2026, one of 7 people that filing names.
7 people named on the filing — 4 holding an executive role and 3 as directors only.
Named as of the 2026-06-11 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Quince Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Quince Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Quince Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Quince Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Quince Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Quince Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/quince-therapeutics-inc-form-d-26000001